{
    "relation": [
        [
            "Citing Patent",
            "US6503939",
            "US6521657",
            "US6544970",
            "US6562857",
            "US6566358",
            "US6583145",
            "US6608068",
            "US6693103",
            "US6713478",
            "US6759408",
            "US6794373",
            "US6835744",
            "US6841568",
            "US6946454",
            "US6964973",
            "US6982261",
            "US7071205",
            "US7081457",
            "US7084151",
            "US7084168",
            "US7091234",
            "US7247625",
            "US7253203",
            "US7323455",
            "US7354915",
            "US7488822",
            "US7514466",
            "US7569564",
            "US7598237",
            "US7645761",
            "US7696246",
            "US7846924",
            "US8309594",
            "US8329690",
            "US8466146",
            "US8476262",
            "US8609712",
            "US8796266",
            "US20040152718 *",
            "US20050054711 *",
            "US20050085470 *",
            "WO2011119194A1"
        ],
        [
            "Filing date",
            "Oct 15, 2001",
            "Oct 30, 2001",
            "May 22, 2002",
            "Jan 9, 2002",
            "Sep 6, 2001",
            "Sep 24, 2002",
            "Dec 11, 2001",
            "Dec 17, 2001",
            "Mar 12, 2003",
            "May 9, 2002",
            "Mar 1, 2002",
            "Apr 24, 2002",
            "Apr 22, 2003",
            "Apr 5, 2002",
            "Nov 18, 2002",
            "Jan 15, 2003",
            "Oct 10, 2003",
            "May 6, 2002",
            "Oct 10, 2003",
            "Jun 6, 2003",
            "Oct 20, 2004",
            "Sep 21, 2004",
            "Mar 17, 2006",
            "Mar 22, 2005",
            "May 21, 2007",
            "Jan 29, 2004",
            "Apr 25, 2005",
            "Feb 9, 2006",
            "Nov 28, 2007",
            "Jun 22, 2007",
            "Jun 23, 2005",
            "Jul 19, 2005",
            "Feb 12, 2009",
            "Apr 8, 2009",
            "Nov 16, 2012",
            "Oct 29, 2010",
            "Sep 14, 2012",
            "May 30, 2013",
            "Oct 10, 2003",
            "Oct 20, 2004",
            "Sep 21, 2004",
            "Dec 23, 2010"
        ],
        [
            "Publication date",
            "Jan 7, 2003",
            "Feb 18, 2003",
            "Apr 8, 2003",
            "May 13, 2003",
            "May 20, 2003",
            "Jun 24, 2003",
            "Aug 19, 2003",
            "Feb 17, 2004",
            "Mar 30, 2004",
            "Jul 6, 2004",
            "Sep 21, 2004",
            "Dec 28, 2004",
            "Jan 11, 2005",
            "Sep 20, 2005",
            "Nov 15, 2005",
            "Jan 3, 2006",
            "Jul 4, 2006",
            "Jul 25, 2006",
            "Aug 1, 2006",
            "Aug 1, 2006",
            "Aug 15, 2006",
            "Jul 24, 2007",
            "Aug 7, 2007",
            "Jan 29, 2008",
            "Apr 8, 2008",
            "Feb 10, 2009",
            "Apr 7, 2009",
            "Aug 4, 2009",
            "Oct 6, 2009",
            "Jan 12, 2010",
            "Apr 13, 2010",
            "Dec 7, 2010",
            "Nov 13, 2012",
            "Dec 11, 2012",
            "Jun 18, 2013",
            "Jul 2, 2013",
            "Dec 17, 2013",
            "Aug 5, 2014",
            "Aug 5, 2004",
            "Mar 10, 2005",
            "Apr 21, 2005",
            "Sep 29, 2011"
        ],
        [
            "Applicant",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Ligand Pharmaceuticals Incorporated",
            "Wyeth",
            "Ligand Pharmaceuticals Incorporated",
            "Wyeth",
            "Ligand Pharmaceuticals Incorporated",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Wyeth",
            "Ligand Pharmaceuticals Incorporated",
            "Wyeth Llc",
            "Wyeth Llc",
            "Wyeth Llc",
            "Wyeth Llc",
            "Wyeth Llc",
            "Wyeth Llc",
            "Wyeth Llc",
            "Lin Zhi",
            "Andrew Fensome",
            "Puwen Zhang",
            "Repros Therapeutics Inc."
        ],
        [
            "Title",
            "Combination regimens using 3,3-substituted indoline derivatives",
            "Thio-oxindole derivatives",
            "Cyclic regimens utilizing indoline derivatives",
            "Cyanopyrroles",
            "Cyclocarbamate derivatives as progesterone receptor modulators",
            "Thio-oxindole derivatives",
            "Indoline derivatives",
            "1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives as progesterone receptor modulators",
            "Cyclocarbamate derivatives as progesterone receptor modulators",
            "Combination regimens using progesterone receptor modulators",
            "Contraceptive methods using benzimidazolones",
            "3,3-substituted indoline derivatives",
            "Thio-oxindole derivatives",
            "Thio-oxindole derivatives",
            "Bicyclic androgen and progesterone receptor modulator compounds and methods",
            "Cyanopyrroles",
            "5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds",
            "Cyclothiocarbamate derivatives as progesterone receptor modulators",
            "5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-\u0192]quinolines as selective progesterone receptor modulator compounds",
            "Indoline derivatives",
            "Thio-oxindole derivatives",
            "6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators",
            "Indoline derivatives",
            "7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators",
            "6-amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators",
            "Cyclocarbamate derivatives as progesterone receptor modulators",
            "Purification of progesterone receptor modulators",
            "Cyclothiocarbamate derivatives as progesterone receptor modulators",
            "7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators",
            "Indoline derivatives",
            "Bicyclic androgen and progesterone receptor modulator compounds and methods",
            "Cyanopyrroles",
            "Purification of progesterone receptor modulators",
            "Cyclothiocarbamate derivatives as progesterone receptor modulators",
            "Cyclothiocarbamate derivatives as progesterone receptor modulators",
            "Cyanopyrroles",
            "Purification of progesterone receptor modulators",
            "Cyclothiocarbamate derivatives as progesterone receptor modulators",
            "5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds",
            "Thio-oxindole derivatives",
            "6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators",
            "Compositions and methods for non-toxic delivery of antiprogestins"
        ]
    ],
    "pageTitle": "Patent US6306851 - Cyclocarbamate and cyclic amide derivatives - Google Patents",
    "title": "",
    "url": "http://www.google.com/patents/US6306851?ie=ISO-8859-1",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 9,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990123.20/warc/CC-MAIN-20150728002310-00078-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 478742387,
    "recordOffset": 478695013,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{5955=Perlman, et. al., described the vitamin D analog 9 as a PR ligand (Tet. Letters, 35, 2295, 1994).}",
    "TableContextTimeStampAfterTable": "{163472=To a solution of 3-Allyloxycarbonylamino-5-(3-chloro-phenyl)-thiophene-2-carboxylic acid methyl ester (5.3 g, 15.1 mmol) in anhydrous THF (30 mL) at room temperature was added a solution of 3.0M MeMgI in ether (20.1 mL, 60.24 mmol). After 30 minutes, the reaction was slowly quenched with H2O (10 mL), treated with saturated NH4OH (100 mL), extracted with ether (200 mL), washed with brine, dried (MgSO4), concentrated, and chromatographed (hexane/ether, 1:4): mp 60-61\ufffd C.; 1H NMR (DMSO-d6) \u03b41.52 (s, 6H), 4.59-4.61 (d, 2H, J=5.35 Hz), 5.22-5.36 (m, 2H), 5.91-6.04 (m, 2H), 7.33-7.67 (m, 5H), 8.89 (s, 1H); MS(EI) m/z 351/353(M+H); Anal. Calc. For C17H18ClNO3S: C, 58.03; H, 5.16; N, 3.98. Found: C, 58.17; H, 5.16; N, 3.97., 156404=To the crude aldehyde, prepared above, in methanol was added a mixture of sulfur (2.55 g, 79.44 mmol), methylcyanoacetate (7.88 g, 79.44 mmol), morpholine (6.92 g, 79.44) and the resulting reaction mixture was refluxed for 16 hours. The unreacted sulfur was filtered off and the filtrates were evaporated leaving behind a black residue. This residue was extracted with ether and washed with H2O. Crystallized from ether hexane (1:5) to obtain white crystals (3.85 g, 14.3 mmol, 50%), mp 85-87\ufffd. 1H NMR (DMSO-d6) \u03b43.75 (s, 3H), 7.18-7.27 (m, 1H), 7.31-7.42 (m, 3H), 7.53 (s, 1H), 7.62 (s, 1H); MS(+APCI) m/z268(M+H); Anal. Calc. For C12H10ClNO2S: C, 53.83; H, 3.76; N, 5.23. Found: C, 53.57; H, 3.37; N, 5.00., 71641=PR antagonists may also be used in contraception. In this context they may be administered alone (Ulmann, et al, Ann. N. Y. Acad. Sci., 261, 248, 1995), in combination with a PR agonist (Kekkonen, et al, Fertility and Sterility, 60, 610, 1993) or in combination with a partial ER antagonist such as tamoxifen (WO 96/19997 A1 Jul. 4, 1996)., 69477=This application claims the benefit of U.S. Provisional Patent Application No. 60/183,015, filed May 4, 1999., 164439=To a solution of [5-(3-Chloro-phenyl)-2-(1-hydroxy-1-methyl-ethyl)-thiophen-3-yl]-carbamic acid allyl ester (0.12 g, 0.34 mmol) in anhydrous THF (5.0 mL) was added KOtBu (0.076 g, 0.068 mmol) and stirred for 15 minutes, quenched with H2O, and in situ crystallization was carried out by adding minimal amount of MeOH to the solution. The white crystals were collected on a B\ufffdchner funnel, mp 123-125\ufffd C. 1H NMR (DMSO-d6) \u03b41.64(s, 6H), 7.05(s, 1H), 7.37-7.48(m, 2H), 7.53-7.56(s, 1H) 7.67-7.68 (m,1H), 10.41(s, 1H); MS(EI) m/z 293/295(M+H); Anal. Calc. For C17H18ClNO3S: C, 57.24; H, 4.12; N, 4.77. Found: C, 56.93; H, 3.92; N, 4.97., 162498=To a solution of 3-Amino-5-(3-chloro-phenyl)-thiophene-2-carboxylic acid methyl ester (15 g, 56.0 mmol) in toluene (200 mL) was added a solution of allyl chloroformate (8.10 g, 67.2 mmol) in toluene (5.0 mL) and the resulting reaction solution was heated under reflux for 3 h. Toluene was stripped down and the crystals were collected and washed with ether/hexane to afford a yellow crystalline compound, mp 101-103\ufffd C. 1H NMR (DMSO-d6) \u03b43.85 (s, 3H), 4.68-4.71 (d, 2H, J=5.46 Hz), 5.26-5.30 (dd, 1H, J=1.35, 9.84 Hz), 5.36-5.42 (dd, 1H, J=1.57, 15.68 Hz), 5.96(m, 2H), 7.50-7.52 (m, 2H), 7.67-7.71 (m, 1H), 7.79 (s, 1H), 8.10 (s, 1H); MS(+APCI) m/z 352(M+H); Anal. Calc. For C16H14ClNO4S: C, 54.63; H, 4.01; N, 3.97. Found: C, 54.05; H, 4.17; N, 3.84.}",
    "textBeforeTable": "Patent Citations All publications cited in this specification are incorporated herein by reference herein. While the invention has been described with reference to a particularly preferred embodiment, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims. IC50: Concentration of a compound that gives half-maximal decrease in 3 nM progesterone induced PRE-luciferase activity (default-nM) with SE. EC50: Concentration of a compound that gives half-maximal increase PRE-luciferase activity (default-nM) with SE. Antiprogestational activity: Compounds that decrease 3 nM progesterone induced PRE-luciferase activity significantly (p<0.05) Progestational activity: Compounds that increase PRE-luciferase activity significantly (p<0.05) compared to vehicle control are considered active. 0.027 0.013 0.001 0.019 3 0.048 0.029 0.002 0.037 2 0.042 0.019 0.002 0.028 1 RU486",
    "textAfterTable": "FR385850A * Title not available JPS63112584A Title not available WO1986003749A1 Dec 18, 1985 Jul 3, 1986 Rorer Int Overseas Bicyclic heteroaryl thiazole compounds, cardiotonic compositions including the same, and their uses WO1991004974A1 Oct 4, 1990 Apr 18, 1991 Boehringer Mannheim Gmbh 2-bicyclo-benzimidazoles, process for their production and drugs containing said compounds WO1991006545A1 Oct 20, 1990 May 16, 1991 Boehringer Mannheim Gmbh Bicyclo-imidazoles, process for producing them and drugs containing them WO1993012085A1 Dec 16, 1992 Jun 24, 1993 Astra Ab Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same WO1994014434A1 Dec 21, 1993 Jul 7, 1994 Smithkline Beecham Corp Endothelin receptor antagonists WO1994029272A1 May 13, 1994 Dec 22, 1994 Astra Ab 1-substituted isatin and oxindole derivatives as inhibitors of acetylcholinesterase WO1995011013A2 Oct 17, 1994",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}